Compare EVH & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVH | RNA |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 251.2M | 227.6M |
| IPO Year | 2015 | 2025 |
| Metric | EVH | RNA |
|---|---|---|
| Price | $2.30 | $13.64 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 20 |
| Target Price | $7.93 | ★ $69.26 |
| AVG Volume (30 Days) | ★ 2.7M | 437.8K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $907,957,000.00 | N/A |
| Revenue This Year | $33.89 | $88.12 |
| Revenue Next Year | $15.84 | $18.11 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.10 | $11.95 |
| 52 Week High | $11.92 | $73.06 |
| Indicator | EVH | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 36.67 | 13.13 |
| Support Level | N/A | $13.06 |
| Resistance Level | $4.20 | $72.75 |
| Average True Range (ATR) | 0.19 | 0.59 |
| MACD | -0.02 | 2.13 |
| Stochastic Oscillator | 18.05 | 86.15 |
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The solutions provided by the company includes: Oncology, Cardiology, Musculoskeletal, Administrative Services, Advanced Illness, Genetic Testing, Physical Medicine, Radiology, and Surgical Management.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.